(MedPage Today) — DENVER — Adding a GLP-1 agonist to psoriasis medication significantly improved outcomes in patients with psoriatic arthritis (PsA) and overweight or obesity, a phase III randomized trial showed.
After 36 weeks, almost a third…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
